What a day for Joseph Edelman’s Perceptive Advisors.
Pfizer’s announcement that it agreed to acquire Array Biopharma for $10.64 billion in cash not only sent the shares of the cancer drug developer soaring, it sharply lifted the stocks of many other biopharmaceutical companies, especially those trying to develop their own cancer treatments.
For
